ProAxsis announced a global licensing agreement with the collaboration of the University of Geneva and the University Hospital of Geneva on a higly novel assay for Cathespin K-dependent periostin cleavage product as a biomarker of bone fragility related to disorders such as osteoporosis. - ProAxsis

Our website is currently being updated and you may experience some limited functionality at this time.

ProAxsis announced a global licensing agreement with the collaboration of the University of Geneva and the University Hospital of Geneva on a higly novel assay for Cathespin K-dependent periostin cleavage product as a biomarker of bone fragility related to disorders such as osteoporosis.

WP_Developer

November 11, 2022

Recent Posts

American Thoracic Society Annual Meeting Washington DC, 19-24 May 2023

November 11, 2022

Association of Medical Diagnostics Manufacturers IVD Regulatory Meeting Bethesda, MD 19-20 April,2023

November 11, 2022

Texas Lung Cancer Conference Austin, TX 30March – 1April 2023

November 11, 2022

Have Any Questions?

Categories

November 11, 2022

Share This :